ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO801

iTRAQ-Based Renal Proteomic Analysis Exploring the Influence of Bone Marrow Derived MSCs on CKD Rats

Session Information

Category: CKD (Non-Dialysis)

  • 1903 CKD (Non-Dialysis): Mechanisms

Authors

  • Bo, Chen, Southwest Medical Univeristy, Luzhou, Sichuan, China
  • Li, Jianchun, Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China
  • Diao, Hui, Affiliated First Hospital of Southwest Medical University, Luzhou, Sichuan, China
  • Liao, Yuan, Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China
  • Wen, Dan, Affiliated First Hospital of Southwest Medical University, Luzhou, Sichuan, China
  • Wang, Li, Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China

Group or Team Name

  • Innovative team of integrated traditional Chinese and western medicine for prophylaxis and treatment of chronic kidney disease
Background

The antifibrosis still represents the final target to treat chronic kidney disease (CKD).Mesenchymal stromal cells (MSCs) have been verified with significant improvement in the therapy of anti-fibrosis in the lastest 10 years. We attempted to clarify iTRAQ-based renal proteomic analysis exploring the new mechanism of MSCs on renal fibrosis.

Methods

Chronic kidney disease (CKD) models were established through combined with adriamycin and adenine in rats. A single intravenous MSCs injection was performed in the early period. Renal fibrosis was evaluated by sirius red staining and extracellular matrix components labeled by immunohistochemistry, respectively. Renal proteomic analysis was analyzed using iTRAQ-based mass spectrometry, and primarily differentially expressed proteins were further assessed by quantitative PCR and Western Blot.

Results

MSCs delivery decreased myofibroblast marker (α-SMA), extracellular matrix expression, and ameliorated the renal function in MSCs group compared to model group. 6,213 proteins were identified, and 40 proteins exhibited significant differences (30 up-regulated, 10 down-regulated) compared to model group. Bioinformatics analysis revealed that these proteins play important roles in biological process, cellular process, biological regulation, response to stimulus, metabolic process, organic substance metabolic process, single-organism process. Lgals3, Ifi47, Armc1 and Mgat3 may play important roles in the improvement of CKD fibrosis by MSCs. Lgals3 protein was down-regulated in MSCs group which has recently been deemed as a new biomarker of renal fibrosis.

Conclusion

We depicted the differently expressed proteins in the early period of MSCs delivery in adriamycin and adenine-induced CKD rat kidney by iTRAQ-based proteomic analysis which may provide valuable information to understand the molecular mechanisms involved in MSCs-based therapy for CKD fibrosis.

Global protein expression patterns in CKD rat kidneys in MSCs group compared to model group

Funding

  • Private Foundation Support